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IT is frequently difficult to predict the
likely course of patients with malignant
diseases. With increasing awareness of
the role of " host " resistance in this
context, many workers have been stimu-
lated into searching for immunological
methods for assessing the strength of this
resistance and its role in prognosis.
As recent evidence suggests that the
major part of the immunological response
to neoplasia is cellular (Hellstrom and
Hellstrom, 1969; Burnet, 1970), it is
obviously important to evaluate cell
mediated reactions in patients with cancer.
The cutaneous delayed hypersensitivity
response to naturally occurring antigens
has been used as an in vivo assessment of
cellular immnunity in subjects with malig-
nant diseases (Solowey and Rapaport,
1965; Hughes and Mackay, 1965). These
workers have demonstrated decreased
responsiveness to the antigens employed
in patients with advanced neoplasia.
Since " positive " results rely upon prior
exposure to the antigen, a " negative "
result to one or more antigens may be
of little relevance in determining anergy.
This defect can be overcome by sensitizing
patients to artificial allergenic chemicals
to which they have not previously been
exposed. One such chemical allergen is
2-4 dinitrochlorobenzene (DNCB) which
will induce 95%o sensitization in normal
individuals (Eilber and Morton, 1970).
In recent studies using this chemical, these
authors have shown that patients who are
anergenic to DNCB have a high incidence
of early recurrence of malignant disease
following surgical resections.
The present study was undertaken to
investigate the relationship between the
initial delayed hypersensitivity reaction
to DNCB, following sensitization, in
patients with gastrointestinal tumours and
their subsequent survival.
MATERIALS AND METHODS
Seventy patients with gastrointestinal
tumours were studied during this investi-
gation. Table I itemizes the tumours studied.
There were 38 males and 32 females and their
ages ranged from 36 to 81 years (mean 63
years). No patients receiving x irradiation,
chemotherapeutic agents or steroids were
included. Patients who were found to be
uraemic, who died during the operation or in
the immediate post-operative period were
also excluded.
Twenty " control " patients were obtained
from the same hospital population. All were
admitted for large bowel investigation and
their consent was obtained before being
included in this study. Their investigations
TABLE I. Sites of Carcinoma in Patients
Studied
Sites of carcinoma
Rectum
Caecuim and colon
Stomach
Oesophagus
Pancreas
Gallbladder
No.
24
18
17
5
5
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revealed no obvious pathology in 7 and
diverticulosis in the remaining 13. There
were 9 male and 11 female patients in this
" control " group, their ages ranging from
44 to 80 years (mean 64 years).
DNCB sensitization and testing.-The
technique employed was adapted from that
of Ratner, Waldorf and Scott (1968).
Patients were sensitized by the application
of 4000 ug of DNCB dissolved in acetone and
applied to a 3 cm2 area of skin on the volar
aspect of the forearm. An occlusive poly-
ethylene dressing was put over the site and
left in position for 4 days.
Sensitivity tests were carried out by
applying 4 Al patch test squares (Imeco A.B.
Stockholm) each impregnated with a different
strength of DNCB in acetone (200, 100, 40
and 2 pg). These squares were applied on the
opposite forearm at least 14 days after
sensitization. The test was read at 48 h,
a " positive " response being recorded when
there was erythema and induration under
the whole of the patch test area.
Patients were then graded according to
their sensitivity as follows:
Negative
i
ii
iii
iv
no reaction to any strength
sensitive to 200 jtg only
sensitive to 200 and 100 lug
sensitive to 200, 100 and
40 ,ug
sensitive to ALL strengths of
DNCB tested.
Follow-up.-All patients were seen at
regular intervals on an out-patient basis
following their treatment in hospital. The
exact date of death was recorded where
appropriate.
RESULTS
The results of the delayed hyper-
sensitivity reactions to DNCB in the
cancer patients and controls are recorded
in Table II. Grades i and ii have been
grouped together because of the small
numbers in these groups.
TABLE II. Delayed Hypersensitivity
Responses to DNCB in Cancer and
Control Patients
Patients Negative I and II III
Cancer 21 15 20
Control 1 5 10
IV
14
4
Total
70
20
The cancerpatientswere dividedalmost
equally between the 4 groups with no
significant difference between the propor-
tions in each group (X2 6-21, d.f. - 3,
P 0 1). All but one ofthe control patients
showed a delayedhypersensitivityreaction
to DNCB and the majority were graded iii.
Ifthe cancer and control patients were
graded as either " positive " or " nega-
tive " (Table III) there was a highly
significant difference between them
P - 0-02 (Fisher's exact test).
TABLE III.-Response to DNCB in Cancer
and Control Groups Expressed as Positive
or Negative
DNCB response
Patients Negative Positive
Cancer
Control
21 49
1 19
When the cancer patients' survival
was compared with their initial DNCB
sensitivity grading (Fig.) there was a
striking correlation between their relative
anergy and their subsequent progress.
All but 2 patients in the Negative and
Grade i categories were already dead at
the time of the review, the longest
recorded survival being only 9 months,
whereas in Grades ii, iii and iv there had
been only 2 deaths and patients had
survived for up to 12 months (which was
the maximum period possible at the time
of this review).
In Table IV the initial DNCB re-
sponses have been compared with the
6-month mortality figures, excluding all
patients who were alive but who had not
yet reached 6 months offollow up. There
was a significant difference between these
TABLE IV. 6-Month Mortality Figures
with Corresponding Initial Response to
DNCB
Initial response to DNCB
At 6months,__ _
Patients Negative I & II III IV
Dead 17 9 2 0
Alive 4 4 14 12
810% 69% 12% 0%
Total
28
34
45%
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+ Cancer patients who have died
* Surviving cancer patients
13
12
11
10
9
8
7
6
5
4
2
-_
Negative
0
Grade I
0
0
0
0
*0--
0
0*
0
+*
+-
0
0@
*000
0@
.
Grade 11 Grade III Grade IV
degree of sensitivity to D.N.C.B.
FIG. Relationship of sensitivity to DNCB with survival.
groups (X2 - 30-68, P < 0-001) with a
linear trend (X2 2836, d.f. = 1,
P < 0-001) from which there was no
significant deviation (x2 2-32, d.f. 2,
P > 0.2).
Overall 4500 of the patients had died
within the first 6 months after their initial
hospital admission and assessment. The
prognosis for Grade iv responders was the
most favourable, with a progressive de-
cline with diminished initial response.
DISCUSSION
The present study has demonstrated
that there is a linear relationship between
thestrength ofthedelayedhypersensitivity
response to an exogenous allergen (DNCB)
and the short-term prognosis in patients
with gastrointestinal cancers. A striking
finding was that patients who were
anergic had only a 20% chance of sur-
viving for 6 months, leading us to question
whether radical surgery is ever justified
in such patients, unless something can be
done to reverse their " anergic " state.
Whether this test will be of value in
predicting long-term survival will have to
await further follow-up studies. Never-
theless, the accurate prognostic assess-
ment of patients with cancer could be
valuable in decisions regarding treatment
regimes.
survival
(months)
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We would suggest that the routine
use of this test in patients with gastro-
intestinal cancer could be a useful addition
to current clinical assessment and might
lead to changes in management.
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